Compare NRGV & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRGV | MNPR |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 727.0M | 587.4M |
| IPO Year | 2021 | 2019 |
| Metric | NRGV | MNPR |
|---|---|---|
| Price | $3.62 | $111.33 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $2.00 | ★ $107.00 |
| AVG Volume (30 Days) | ★ 5.2M | 263.1K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.57 | ★ 54.99 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $203,671,000.00 | N/A |
| Revenue This Year | $28.93 | N/A |
| Revenue Next Year | $16.69 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 340.86 | N/A |
| 52 Week Low | $1.60 | $29.18 |
| 52 Week High | $6.65 | $124.82 |
| Indicator | NRGV | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 51.89 | 49.18 |
| Support Level | $2.95 | $102.88 |
| Resistance Level | $4.11 | $114.60 |
| Average True Range (ATR) | 0.32 | 6.56 |
| MACD | 0.07 | -1.78 |
| Stochastic Oscillator | 58.65 | 25.29 |
Energy Vault Holdings Inc is a diversified portfolio of energy storage solutions to third parties, including proprietary gravity, battery, and green hydrogen-based technologies, supported by technology-agnostic energy management software and integration capabilities. Geographical presence in the United States, Australia, and other countries. The majority of its revenue comes from Australia.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.